These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37528748)

  • 21. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
    Pittman ME; Edwards SW; Ives C; Mortensen HM
    Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiatives, Concepts, and Implementation Practices of the Findable, Accessible, Interoperable, and Reusable Data Principles in Health Data Stewardship: Scoping Review.
    Inau ET; Sack J; Waltemath D; Zeleke AA
    J Med Internet Res; 2023 Aug; 25():e45013. PubMed ID: 37639292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. sAOP: linking chemical stressors to adverse outcomes pathway networks.
    Aguayo-Orozco A; Audouze K; Siggaard T; Barouki R; Brunak S; Taboureau O
    Bioinformatics; 2019 Dec; 35(24):5391-5392. PubMed ID: 31329252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse outcome pathways: opportunities, limitations and open questions.
    Leist M; Ghallab A; Graepel R; Marchan R; Hassan R; Bennekou SH; Limonciel A; Vinken M; Schildknecht S; Waldmann T; Danen E; van Ravenzwaay B; Kamp H; Gardner I; Godoy P; Bois FY; Braeuning A; Reif R; Oesch F; Drasdo D; Höhme S; Schwarz M; Hartung T; Braunbeck T; Beltman J; Vrieling H; Sanz F; Forsby A; Gadaleta D; Fisher C; Kelm J; Fluri D; Ecker G; Zdrazil B; Terron A; Jennings P; van der Burg B; Dooley S; Meijer AH; Willighagen E; Martens M; Evelo C; Mombelli E; Taboureau O; Mantovani A; Hardy B; Koch B; Escher S; van Thriel C; Cadenas C; Kroese D; van de Water B; Hengstler JG
    Arch Toxicol; 2017 Nov; 91(11):3477-3505. PubMed ID: 29051992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The AOP-DB RDF: Applying FAIR Principles to the Semantic Integration of AOP Data Using the Research Description Framework.
    Mortensen HM; Martens M; Senn J; Levey T; Evelo CT; Willighagen EL; Exner T
    Front Toxicol; 2022; 4():803983. PubMed ID: 35295213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?
    Coady K; Browne P; Embry M; Hill T; Leinala E; Steeger T; Maślankiewicz L; Hutchinson T
    Integr Environ Assess Manag; 2019 Jul; 15(4):633-647. PubMed ID: 30908812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.
    Arnesdotter E; Gijbels E; Dos Santos Rodrigues B; Vilas-Boas V; Vinken M
    Methods Mol Biol; 2022; 2425():521-535. PubMed ID: 35188645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining the Biologically Plausible Taxonomic Domain of Applicability of an Adverse Outcome Pathway: A Case Study Linking Nicotinic Acetylcholine Receptor Activation to Colony Death.
    Jensen MA; Blatz DJ; LaLone CA
    Environ Toxicol Chem; 2023 Jan; 42(1):71-87. PubMed ID: 36263952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse Outcome Pathways can drive non-animal approaches for safety assessment.
    Burden N; Sewell F; Andersen ME; Boobis A; Chipman JK; Cronin MT; Hutchinson TH; Kimber I; Whelan M
    J Appl Toxicol; 2015 Sep; 35(9):971-5. PubMed ID: 25943792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AOP Report: Adverse Outcome Pathways for Aromatase Inhibition or Androgen Receptor Agonism Leading to Male-Biased Sex Ratio and Population Decline in Fish.
    Ankley GT; Santana-Rodriguez K; Jensen KM; Miller DH; Villeneuve DL
    Environ Toxicol Chem; 2023 Apr; 42(4):747-756. PubMed ID: 36848318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in data interoperability to support computational toxicology and chemical safety evaluation.
    Watford S; Edwards S; Angrish M; Judson RS; Paul Friedman K
    Toxicol Appl Pharmacol; 2019 Oct; 380():114707. PubMed ID: 31404555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
    Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linking Mitochondrial Dysfunction to Organismal and Population Health in the Context of Environmental Pollutants: Progress and Considerations for Mitochondrial Adverse Outcome Pathways.
    Dreier DA; Mello DF; Meyer JN; Martyniuk CJ
    Environ Toxicol Chem; 2019 Aug; 38(8):1625-1634. PubMed ID: 31034624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
    Vinken M
    Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse Outcome Pathway 'Footprinting': A Novel Approach to the Integration of 21st Century Toxicology Information into Chemical Mixtures Risk Assessment.
    Lambert JC
    Toxics; 2022 Dec; 11(1):. PubMed ID: 36668763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural language processing in toxicology: Delineating adverse outcome pathways and guiding the application of new approach methodologies.
    Corradi MPF; de Haan AM; Staumont B; Piersma AH; Geris L; Pieters RHH; Krul CAM; Teunis MAT
    Biomater Biosyst; 2022 Aug; 7():100061. PubMed ID: 36824484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
    Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
    Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an adverse outcome pathway network for nephrotoxicity.
    Barnes DA; Firman JW; Belfield SJ; Cronin MTD; Vinken M; Janssen MJ; Masereeuw R
    Arch Toxicol; 2024 Mar; 98(3):929-942. PubMed ID: 38197913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.